ACH-3102: Phase IIa started

Achillion began an open-label Phase IIa trial to evaluate 225 mg oral ACH-3102 on day 1 and 75 mg ACH-3102 once daily thereafter in combination with twice-daily ribavirin in up to 16 treatment-naive p...